Clinical research progress of efgartigimod in the treatment of general-ized myasthenia gravis
10.12092/j.issn.1009-2501.2025.05.017
- VernacularTitle:艾加莫德治疗全身型重症肌无力的临床研究进展
- Author:
Shu LIU
1
;
Chunhui SUN
;
Zhirong TAN
;
Man XING
Author Information
1. 青岛市第三人民医院药学部,青岛 370200,山东
- Publication Type:Journal Article
- Keywords:
efgartigimod;
myasthenia gravis;
clini-cal research;
safety
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2025;30(5):714-720
- CountryChina
- Language:Chinese
-
Abstract:
Myasthenia gravis(MG)is a chronic autoimmune disease that causes partial or system-ic skeletal muscle weakness and fatigue.Efgartigi-mod is an antibody fragment targeting the Fc re-ceptor in newborns,which clears pathogenic immu-noglobulin G antibodies through a unique mecha-nism.Efgartigimod is used to treat systemic myas-thenia gravis safely and efficiently,which can signif-icantly improve muscle strength and quality of life for patients.This article reviews pharmacological,clinical research,and safety of efgartigimod,in or-der to providing reference for its clinical treatment in systemic myasthenia gravis(gGM).
